Vaxart urges shareholders to back its six director nominees at July 16 annual meeting amid dissident challenge

Vaxart, Inc

Vaxart, Inc

VXRT

0.00
  • Vaxart urged shareholders to vote FOR all six board nominees on its white proxy card ahead of the July 16 annual meeting.
  • The campaign targets a dissident slate tied to Daniel Houle, arguing the nominees lack clinical-stage biotech or vaccine development experience.
  • Vaxart said it made multiple settlement offers, framing the dispute as Houle seeking a board seat rather than a value plan.
  • The company highlighted continued BARDA funding for its lead COVID-19 program, a USD 40 million 2025 raise, a USD 25 million share purchase agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606260800PRIMZONEFULLFEED9753056) on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.